RESUMEN
A challenge in the treatment of Staphylococcus aureus infections is the high prevalence of methicillin-resistant S. aureus (MRSA) strains and the formation of non-growing, dormant 'persister' subpopulations that exhibit high levels of tolerance to antibiotics and have a role in chronic or recurrent infections. As conventional antibiotics are not effective in the treatment of infections caused by such bacteria, novel antibacterial therapeutics are urgently required. Here we used a Caenorhabditis elegans-MRSA infection screen to identify two synthetic retinoids, CD437 and CD1530, which kill both growing and persister MRSA cells by disrupting lipid bilayers. CD437 and CD1530 exhibit high killing rates, synergism with gentamicin, and a low probability of resistance selection. All-atom molecular dynamics simulations demonstrated that the ability of retinoids to penetrate and embed in lipid bilayers correlates with their bactericidal ability. An analogue of CD437 was found to retain anti-persister activity and show an improved cytotoxicity profile. Both CD437 and this analogue, alone or in combination with gentamicin, exhibit considerable efficacy in a mouse model of chronic MRSA infection. With further development and optimization, synthetic retinoids have the potential to become a new class of antimicrobials for the treatment of Gram-positive bacterial infections that are currently difficult to cure.
Asunto(s)
Antibacterianos/clasificación , Antibacterianos/farmacología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Retinoides/farmacología , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Animales , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Benzoatos/química , Benzoatos/farmacología , Benzoatos/uso terapéutico , Benzoatos/toxicidad , Caenorhabditis elegans/efectos de los fármacos , Caenorhabditis elegans/microbiología , Muerte Celular/efectos de los fármacos , Línea Celular , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Gentamicinas/farmacología , Gentamicinas/uso terapéutico , Humanos , Membrana Dobles de Lípidos/química , Staphylococcus aureus Resistente a Meticilina/citología , Staphylococcus aureus Resistente a Meticilina/genética , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Ratones , Pruebas de Sensibilidad Microbiana , Simulación de Dinámica Molecular , Mutación , Naftoles/química , Naftoles/farmacología , Naftoles/uso terapéutico , Naftoles/toxicidad , Retinoides/química , Retinoides/uso terapéutico , Retinoides/toxicidadRESUMEN
Two new naphthalenone compounds were isolated from green walnut husks of Juglans mandshurica and their structures were identified as 4-butoxybutoxy-5,8-dihydroxy-3,4-dihydro-2H-naphthalen-1-one (1), 4-ethoxyethoxy-5,8-dihydroxy-3,4-dihydro-2H-naphthalen-1-one (2). Compounds 1 and 2 were named as Juglanstetralone A (1) and Juglanstetralone B (2). Compound 1 showed more significant anti-tumor activity than 2 against gastric cancer BGC-823 cells, wih the IC50 of 125.89 (g(mL(-1).
Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Carcinoma/tratamiento farmacológico , Juglans/química , Naftoles/uso terapéutico , Nueces/química , Neoplasias Gástricas/tratamiento farmacológico , Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/farmacología , Línea Celular Tumoral , Humanos , Naftoles/aislamiento & purificación , Naftoles/farmacología , Fitoterapia , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéuticoRESUMEN
Two new 7,6'-coupled naphthylisoquinolines, namely ancistrotectorines A (1) and B (2), two new 5,3'-coupled naphthylisoquinolines, namely ancistrotectorines C (3) and D (4), and one new 7,8-coupled naphthylisoquinoline, namely ancistrotectorine E (5), together with 9 known naphthylisoquinoline alkaloids, hamatine (6), ancistrobertsonine B (7), ancistrocladinine (8), hamatinine (9), ancistrotanzanine A (10), ancistrotanzanine B (11), ancistrotectoriline B (12), 7-epi-ancistrobrevine D (13), and ancistrotectorine (14), were isolated from the 70% EtOH extract of Ancistrocladus tectorius. Their structures were elucidated based on the extensive analysis of spectroscopic data (1D, 2D NMR and MS). Compound 5 exhibited inhibitory activities against HL-60, K562 and U937 cell lines with IC50 values of 1.70, 4.18 and 2.56 µM respectively.
Asunto(s)
Isoquinolinas/aislamiento & purificación , Leucemia/tratamiento farmacológico , Magnoliopsida/química , Naftoles/uso terapéutico , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Células HL-60 , Humanos , Concentración 50 Inhibidora , Isoquinolinas/química , Isoquinolinas/farmacología , Células K562 , Estructura Molecular , Naftoles/química , Naftoles/aislamiento & purificación , Naftoles/farmacología , Fitoterapia , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Tallos de la Planta/química , Células U937RESUMEN
Natural agents with the immunomodulating property have been gaining traction to be employed in the complementary therapy of cancer because the ineffectiveness of numerous therapeutic strategies may be related in part to the tumor-induced immunosuppressive phenotypes, especially regulatory T (Treg) cells found in the tumor microenvironment. The present study was undertaken to examine whether HS-1793, synthetic resvertrol analog free from the restriction of metabolic instability and high dose requirement of resveratrol, induces an in vivo anti-tumor effect in FM3A tumor bearing mice through the suppression of Treg cells, which contribute to an increase in tumor specific cytotoxic T cell responses. Intraperitoneal injections of HS-1793 showed not only therapeutic benefits on established tumors, but also preventive anti-tumor effects. Treg cells (CD4+CD25+Foxp3+ cells) were significantly reduced in the total splenocytes as well as tumor tissues from HS-1793-administered mice, and the production of TGF-ß inducing Treg showed a similar pattern. On the contrary, the administration of HS-1793 increased IFN-γ-expressing CD8+ T cells, upregulated IFN-γ production, and enhanced the cytotoxicity of splenocytes against FM3A tumor cells both in therapeutic and preventive experimental animals. These results demonstrated the suppressive role of HS-1793 on the function of Treg cells contributing to tumor specific cytotoxic T lymphocyte responses in tumor-bearing mice, which explained the underlying mechanism of the anti-tumor immunity of HS-1793.
Asunto(s)
Antineoplásicos/farmacología , Naftoles/farmacología , Neoplasias/inmunología , Resorcinoles/farmacología , Linfocitos T/efectos de los fármacos , Animales , Antineoplásicos/uso terapéutico , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Femenino , Ratones , Ratones Endogámicos C3H , Naftoles/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Resorcinoles/uso terapéutico , Bazo/citología , Bazo/inmunología , Linfocitos T/inmunología , Carga Tumoral/efectos de los fármacosRESUMEN
OBJECTIVE: In our previous study, we had isolated a series of lignan compounds, termed vitexins, from the seed of Chinese herb Vitex negundo and found broad antitumor activities of these compounds in many cancer xenograft models and cell lines. This study was aimed to determine the antitumor effect of purified vitexin compound 1 (VB1) on choriocarcinoma in vitro and in vivo. MATERIALS AND METHODS: The severe combined immunodeficiency mouse model of choriocarcinoma was established to investigate the in vivo effect of VB1. Its effect on proliferation and apoptosis in JEG-3 cell line was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, colony formation assay and flow cytometry, respectively. The expression of caspase-3, Bcl-2, and some molecules involved in the mammalian target of rapamycin (mTOR) signaling was detected by Western blot. RESULTS: Vitexin compound 1 significantly inhibited the growth of choriocarcinoma in severe combined immunodeficient mice and reduced the serum ß-human chorionic gonadotropin level. Vitexin compound 1 inhibited cell proliferation, induced apoptosis, and inhibited the mTOR signaling in JEG-3 cell line. CONCLUSION: Vitexin compound 1 could inhibit choriocarcinoma via inducing cell apoptosis and suppressing the mTOR pathway.
Asunto(s)
Apigenina/uso terapéutico , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Coriocarcinoma/tratamiento farmacológico , Neoplasias Uterinas/tratamiento farmacológico , Animales , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/uso terapéutico , Apigenina/química , Apigenina/aislamiento & purificación , Línea Celular Tumoral , Coriocarcinoma/patología , Regulación hacia Abajo/efectos de los fármacos , Femenino , Guayacol/análogos & derivados , Guayacol/aislamiento & purificación , Guayacol/uso terapéutico , Humanos , Ratones , Ratones Desnudos , Ratones SCID , Modelos Biológicos , Naftoles/aislamiento & purificación , Naftoles/uso terapéutico , Embarazo , Carga Tumoral/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Neoplasias Uterinas/patología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
SUMMARY: The main component of the metabolic by-products of fermentation by Propionibacterium freudenreichii ET-3 is 1,4-dihydroxy-2-naphthoic acid (DHNA), which has a naphthoquinone skeleton, as in vitamin K2. This study showed that DHNA improved bone mass reduction with osteoporosis model mice caused by FK506. INTRODUCTION: Growth of the intestinal bacterium Lactobacillus bifidus is specifically facilitated by DHNA. The present study used osteoporosis model mice to investigate the effects of DHNA on bone remodeling. METHODS: FK506, an immunosuppressant, was used to prepare osteoporosis model mice. Thirty mice were divided into three groups: FK group, FK+DHNA group, and control group. In the FK group, FK506 was administered to induce bone mass reduction. In the FK-DHNA group, FK506 and DHNA were administered concurrently to observe improvements in bone mass reduction. To ascertain systemic and local effects of DHNA, we investigated systemic pathological changes in colon, kidney function and cytokine dynamics, and morphological and organic changes in bone and osteoclast dynamics as assessed by culture experiments. RESULTS: Compared to the FK group without DHNA, colon damage and kidney dysfunction were milder for FK+DHNA group, and production of inflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha) was more suppressed. Furthermore, compared to the group without DHNA, histological analyses and radiography showed that bone resorption was suppressed for the DHNA group. Culture experiments using osteoclasts from murine bone marrow showed osteoclast suppression for the DHNA group compared to the group without DHNA. CONCLUSION: These results show that DHNA has some effects for improving bone mass reduction caused by FK506.
Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Naftoles/uso terapéutico , Osteoporosis/prevención & control , Animales , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Células Cultivadas , Colon/efectos de los fármacos , Colon/patología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Ingestión de Alimentos/efectos de los fármacos , Fémur/efectos de los fármacos , Fémur/patología , Fémur/fisiopatología , Inmunosupresores , Mediadores de Inflamación/metabolismo , Riñón/efectos de los fármacos , Riñón/fisiopatología , Masculino , Ratones , Ratones Endogámicos ICR , Osteoclastos/efectos de los fármacos , Osteoclastos/patología , Osteoporosis/inducido químicamente , TacrolimusRESUMEN
Bioassay-guided fractionation of the neutral extract of the bark of Sarcomelicope megistophylla resulted in the isolation of the new nor-neolignan sarcomeginal ( 1), together with the known ailanthoidol ( 2) and (+/-)-seco-isolariciresinol ( 3). The structure of 1 was determined by spectroscopic means. Estrogenic activity of the isolated compounds was tested using estrogen receptor-positive MCF7 and estrogen receptor-negative MDA-MB-231 human mammary adenocarcinoma cell lines. Compound 3 displayed significant estrogenic activity.
Asunto(s)
Antineoplásicos Hormonales/farmacología , Benzofuranos/farmacología , Lignanos/farmacología , Lignina/farmacología , Naftoles/farmacología , Fitoterapia , Extractos Vegetales/farmacología , Receptores de Estrógenos/efectos de los fármacos , Rutaceae , Adenocarcinoma/tratamiento farmacológico , Antineoplásicos Hormonales/administración & dosificación , Antineoplásicos Hormonales/uso terapéutico , Benzofuranos/administración & dosificación , Benzofuranos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Concentración 50 Inhibidora , Lignanos/administración & dosificación , Lignanos/uso terapéutico , Lignina/administración & dosificación , Lignina/uso terapéutico , Naftoles/administración & dosificación , Naftoles/uso terapéutico , Corteza de la Planta , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
S-8921 is a sodium/bile acid transport inhibitor under development by Shionogi for the potential treatment of hyperlipidemia. As of June 2000, phase I trials had commenced in Japan and were planned in Europe [370602]. S-8921 acts by altering sodium-dependent transport mechanisms of the brush-borders in the intestinal mucosa, causing bile acids that re-enter the intestine to be excreted rather than reabsorbed [281476].
Asunto(s)
Anticolesterolemiantes/farmacología , Ácidos y Sales Biliares/metabolismo , Proteínas Portadoras/antagonistas & inhibidores , Drogas en Investigación , Hidroxiesteroide Deshidrogenasas , Glicoproteínas de Membrana , Naftoles/farmacología , Animales , Anticolesterolemiantes/uso terapéutico , Transporte Biológico/efectos de los fármacos , Ensayos Clínicos Fase I como Asunto , Evaluación Preclínica de Medicamentos , Predicción , Glucurónidos/metabolismo , Humanos , Hiperlipidemias/sangre , Hiperlipidemias/tratamiento farmacológico , Hiperlipidemias/orina , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Estructura Molecular , Naftoles/química , Naftoles/farmacocinética , Naftoles/uso terapéuticoRESUMEN
Naphthylisoquinoline alkaloid-containing extracts from species of the families Dioncophyllaceae and Ancistrocladaceae and purified alkaloids derived therefrom were shown to exhibit antiparasitic activity in Plasmodium berghei-infected mice. Several extracts and alkaloids, especially dioncophylline C and dioncopeltine A, isolated from Triphyophyllum peltatum (Dioncophyllaceae), displayed high levels of activity. Dioncopeltine A was able to suppress parasitemia almost totally, while dioncophylline C cured infected mice completely after oral treatment with 50 mg kg of body weight(-1) day(-1) for 4 days without noticeable toxic effects. Analysis of the dose-response relationship of dioncophylline C revealed a 50% effective dosage (ED50) of 10.71 mg kg(-1) day(-1) under these conditions. Although four daily treatments with 50 mg kg(-1) day(-1) are needed to achieve radical cure, one oral dose is sufficient to kill 99.6% of the parasites. Intravenous application of dioncophylline C is even more effective, with an ED50 of 1.90 mg kg(-1) day(-1) and no noticeable toxic effects. The compound also suppressed more established P. berghei infections when orally applied at day 3 after infection. Both dioncopeltine A and dioncophylline C are active against the chloroquine-resistant P. berghei Anka CRS parasites. Sustained release of these compounds at 20 mg kg(-1) day(-1) by implanted miniosmotic pumps exhibited curative effects. The naphthylisoquinoline alkaloids are therefore promising new antimalarial agents.
Asunto(s)
Antimaláricos/uso terapéutico , Isoquinolinas/uso terapéutico , Malaria/tratamiento farmacológico , Naftoles/uso terapéutico , Plasmodium berghei , Animales , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Ratones , Plasmodium berghei/efectos de los fármacosRESUMEN
The antibiotic activity of new synthetic isoxazolylnaphthoquinone imines was studied. Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were resistant to the four compounds studied (MIC > 128 micrograms ml-1), but Staphylococcus aureus ATCC 25923, ATCC 29213 and 30 clinical isolates of Staph. aureus were inhibited by 2-hydroxy-N-(3,4-dimethyl-5-isoxazolyl)-1,4-naphthoquinone-4-imine (I). This compound diminished bloodstream infection of mice injected i.m. with Staph. aureus; septicaemia decayed significantly when I was applied at the beginning of the infection while when I was given 3 d after bacterial challenge, a significant protection was afforded. Bactericidal activity in serum increased during the 5 h after I was administered i.p. The acetyl derivative of I had a high MIC but when inoculated orally in mice decreased the Staph. aureus counts in circulation. This protection occurred only when the schedule of administration started close to the bacterial challenge. Antibiotic activity in vivo may be associated with in vitro effects.
Asunto(s)
Antiinfecciosos/uso terapéutico , Isoxazoles/uso terapéutico , Naftoles/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Antiinfecciosos/farmacología , Femenino , Isoxazoles/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Naftoles/farmacología , Naftoquinonas , Infecciones Estafilocócicas/prevención & controlRESUMEN
Airway hyperresponsiveness is a key feature of asthma, and attenuating airway hyperresponsiveness is an important part of asthma therapy. In the present study we examined the inhibitory effect of a potent 5-lipoxygenase inhibitor, FR110302, on airway hyperresponsiveness induced by ozone exposure in guinea pigs and dogs. Respiratory resistance (Rrs) was measured by a forced oscillation method. Airway responsiveness was determined from the dose-response curve of Rrs to acetylcholine. Guinea pigs were exposed to 2.5 ppm ozone for 1 h. In a control group of guinea pigs, delta log PC100 (the index of the ozone-induced airway hyperresponsiveness) was 0.58 +/- 0.04 (log mg/ml). Treatment with FR110302 (10 or 100 mg/kg p.o.) significantly diminished delta log PC100 (10 mg/kg: 0.22 +/- 0.10; 100 mg/kg; 0.11 +/- 0.06). Dogs were exposed to 3 ppm ozone for 2 h. In a control group of dogs, delta log Dmin (another index of the ozone-induced airway hyperresponsiveness) was 1.24 +/- 0.15 (log unit). Treatment with FR110302 (1 or 3.2 mg/kg p.o.) significantly diminished delta log Dmin (1 mg/kg: 0.60 +/- 0.18; 3.2 mg/kg: 0.27 +/- 0.12). These results suggest that FR110302 may be a useful drug for attenuating airway hyperresponsiveness in asthmatic patients.
Asunto(s)
Resistencia de las Vías Respiratorias/efectos de los fármacos , Hiperreactividad Bronquial/tratamiento farmacológico , Inhibidores de la Lipooxigenasa/uso terapéutico , Naftoles/uso terapéutico , Quinolinas/uso terapéutico , Acetilcolina/farmacología , Administración Oral , Animales , Perros , Cobayas , Inhibidores de la Lipooxigenasa/administración & dosificación , Inhibidores de la Lipooxigenasa/farmacología , Naftoles/administración & dosificación , Naftoles/farmacología , Ozono/toxicidad , Quinolinas/administración & dosificación , Quinolinas/farmacologíaRESUMEN
Ambrein reduced the blood glucose level of normal and moderately alloxan-diabetic rats but did not reduce the blood glucose levels of severely-diabetic rats. Ambrein did not reduce the hyperglycemia of glucose-loaded rats also given mannoheptulose but it reduced the hyperglycemia of glucose-loaded rats in the absence of mannoheptulose. Results suggested that the hypoglycemic activity of ambrein may be mediated by enhanced glucose utilization.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Naftoles/uso terapéutico , Administración Oral , Animales , Masculino , Ratas , Ratas Endogámicas , Índice de Severidad de la Enfermedad , TriterpenosRESUMEN
Frente a la necessidad de hallar neuveos fármacos contra el agente etiológico de la enfermedad de Chagas y en base a las propiedades biológicas y terapéuticas de naftoquinonas e isoxazoles, se resolvió estudiar el efecto de tres isoxazolilnaftoquinonas (Fig. 1) sobre el desarrollo del Trypanosoma cruzi in-vitro e in-vivo. Para evaluar la acción de las drogas sobre los epimastigotes se realizaron curvas de crecimiento con distintas concentraciones de 2-hidroxi-N-(3,4-dimetil-5-isoxazolil)-1,4-naftoquinina-4-imina (I), N-(3,4-dimetil-5-isoxazolil)-4-amino-1,2 naftoquinona (II), 2-acetil-N-(3,4-dimetil-5-isoxazolil)-1,4-naftoquinona-imina (III) y Nifurtimox como droga de referencia. Los estudios sobre la forma de tripomastigote se realizaron sobre ratones BALB/c de dos meses de edad, evaluado parasistemia en el día 13 post-infección. Los resultados obtenidos con epimastigotes mostraron que todas las drogas indujeron alteraciones consistentes es disminución de movilidad, vacuolización, pérdida de viabilidad y/o lisis de los parásitos (Fig. 2 y 3). En los tratamientos sobre tripomastigotes los resultados más concluyentes se presentaron con I que produjo una reducción de la parasitemia respecto a los controles no tratados (Fig 4) (AU)
Asunto(s)
Animales , Ratones , Trypanosoma cruzi/efectos de los fármacos , Isoxazoles/farmacología , Naftoles/farmacología , Naftoquinonas/farmacología , Tripanocidas/farmacología , Isoxazoles/toxicidad , Isoxazoles/uso terapéutico , Nifurtimox/farmacología , Enfermedad de Chagas/tratamiento farmacológico , Trypanosoma cruzi/crecimiento & desarrollo , Ratones Endogámicos BALB C , Naftoles/toxicidad , Naftoles/uso terapéutico , Naftoquinonas/toxicidad , Naftoquinonas/uso terapéutico , Tripanocidas/toxicidad , Tripanocidas/uso terapéutico , Evaluación Preclínica de MedicamentosRESUMEN
Frente a la necessidad de hallar neuveos fármacos contra el agente etiológico de la enfermedad de Chagas y en base a las propiedades biológicas y terapéuticas de naftoquinonas e isoxazoles, se resolvió estudiar el efecto de tres isoxazolilnaftoquinonas (Fig. 1) sobre el desarrollo del Trypanosoma cruzi in-vitro e in-vivo. Para evaluar la acción de las drogas sobre los epimastigotes se realizaron curvas de crecimiento con distintas concentraciones de 2-hidroxi-N-(3,4-dimetil-5-isoxazolil)-1,4-naftoquinina-4-imina (I), N-(3,4-dimetil-5-isoxazolil)-4-amino-1,2 naftoquinona (II), 2-acetil-N-(3,4-dimetil-5-isoxazolil)-1,4-naftoquinona-imina (III) y Nifurtimox como droga de referencia. Los estudios sobre la forma de tripomastigote se realizaron sobre ratones BALB/c de dos meses de edad, evaluado parasistemia en el día 13 post-infección. Los resultados obtenidos con epimastigotes mostraron que todas las drogas indujeron alteraciones consistentes es disminución de movilidad, vacuolización, pérdida de viabilidad y/o lisis de los parásitos (Fig. 2 y 3). En los tratamientos sobre tripomastigotes los resultados más concluyentes se presentaron con I que produjo una reducción de la parasitemia respecto a los controles no tratados (Fig 4)
Asunto(s)
Animales , Ratones , Isoxazoles/farmacología , Naftoles/farmacología , Naftoquinonas/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Enfermedad de Chagas/tratamiento farmacológico , Isoxazoles/toxicidad , Isoxazoles/uso terapéutico , Ratones Endogámicos BALB C , Naftoles/toxicidad , Naftoles/uso terapéutico , Naftoquinonas/uso terapéutico , Naftoquinonas/toxicidad , Nifurtimox/farmacología , Evaluación Preclínica de Medicamentos , Tripanocidas/uso terapéutico , Tripanocidas/toxicidad , Trypanosoma cruzi/crecimiento & desarrolloRESUMEN
Knowing the need for new drugs against the etiologic agent of Chagas disease and considering the biological properties of naphthoquinones and isoxazoles, the effect of three isoxazolyl-naphthoquinones on the growth of Trypanosoma cruzi was studied. To evaluate the activity of the compounds on epimastigote forms, growth curves with different concentrations of 2-hydroxi-N-(3,4-dimethyl-5-isoxazolyl)-1,4-naphthoquinone-4 -imine (I), N-(3,4-dimethyl-5-isoxazolyl)-4-amino-1,2-naphthoquinone (II), 2-acetyl-N-(3,4-dimethyl-5-isoxazolyl)-1,4-naphthoquinone-imine (III) and Nifurtimox as reference drug were made. The studies on the trypomastigote form were performed on two month old BALB/c mice, evaluating parasitemia on day 13 post infection. The results obtained with epimastigotes showed that all drugs induced alterations in motility, morphology, viability and/or lysis of parasites. For the treatments on trypomastigotes the best results were obtained with (I) which reduced parasitemia compared to untreated controls.
Asunto(s)
Isoxazoles/farmacología , Naftoles/farmacología , Naftoquinonas/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Animales , Enfermedad de Chagas/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Isoxazoles/uso terapéutico , Isoxazoles/toxicidad , Ratones , Ratones Endogámicos BALB C , Naftoles/uso terapéutico , Naftoles/toxicidad , Naftoquinonas/uso terapéutico , Naftoquinonas/toxicidad , Nifurtimox/farmacología , Tripanocidas/uso terapéutico , Tripanocidas/toxicidad , Trypanosoma cruzi/crecimiento & desarrolloRESUMEN
Hepatoprotective effect of andrographolide (the major active diterpenoid lactone of the plant Andrographis paniculata) was studied on acute hepatitis induced in rats by single dose of galactosamine (800 mg/kg, ip)/paracetamol (3g/kg, po). Hepatoprotective activity was monitored by estimating the serum transaminases (GOT and GPT), alkaline phosphatase and bilirubin in serum, hepatic triglycerides, and by histopathological changes in the livers of experimental rats. Pre-treatment and/or post-treatment of rats at different time intervals with different doses of andrographolide in the two experimental models of hepatotoxicity showed that treatment of rats with 400 mg/kg, ip or 800 mg/kg, po, 48, 24 and 2 h before galactosamine administration or with 200 mg/kg, ip, 1, 4 and 7 h after paracetamol challenge leads to complete normalisation of toxin-induced increase in the levels of all the five biochemical parameters, and significantly ameliorates toxin-induced histopathological changes in the livers of experimental rats. The results confirmed the in vivo hepatoprotective effect of andrographolide against galactosamine or paracetamol-induced hepatotoxicity in rats. Since the protective effect of andrographolide was observed in two types of intoxication, which are very different in their primary mechanism of inducing hepatotoxicity, it is suggested that protective mechanisms of andrographolide which are not specific to galactosamine or paracetamol toxicity may be responsible for the hepatoprotective activity of the compound.
Asunto(s)
Diterpenos , Hepatitis Animal/tratamiento farmacológico , Hígado/efectos de los fármacos , Naftoles/farmacología , Acetaminofén , Animales , Modelos Animales de Enfermedad , Femenino , Galactosamina , Hepatitis Animal/inducido químicamente , Hepatitis Animal/patología , Hígado/patología , Pruebas de Función Hepática , Masculino , Naftoles/uso terapéutico , Extractos Vegetales/farmacología , RatasRESUMEN
A certain role in the outcome of virus infection of cells was assumed to belong to cell membrane lipids peroxidation. The influence of known inhibitors of lipid peroxidation, beta-naphthol and ionol, on HeLa cells infection with human adenovirus type 2 was studied. These antioxidants in certain concentrations were found to be capable of effectively inhibiting virus infection of HeLa cell cultures. At the same time, beyond these concentration levels these antioxidants did not inhibit but stimulated virus infection of HeLa cell cultures. It is concluded that inhibition of virus infection of cells by antioxidants in moderate concentrations is due to their blocking of membrane lipids peroxidation. The opposite effect of antioxidants in much higher or lower concentrations may be due to their membranotropic effect which enhances the development of virus infection. The results of the study attest to the possible use of antioxidants in appropriate concentrations for control of virus infection.